Evidence map›Paper›PMID 30257071›Full record

ArticleChemMedChem2018

Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120.

Francesca Curreli, Dmitry S Belov, Shahad Ahmed, Ranjith R Ramesh, Alexander V Kurkin, Andrea Altieri, Asim K Debnath

Abstract read
In one paragraph

Article in ChemMedChem, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Antiviral Activity and Crystal Structures of HIV-1 gp120 Antagonists.International journal of molecular sciences · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Francesca CurreliLaboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY, 10065, USA.
Dmitry S BelovEDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Boulevard 75, 77-101b, 119992, Moscow, Russia.
Shahad AhmedLaboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY, 10065, USA.
Ranjith R RameshLaboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY, 10065, USA.
Alexander V KurkinEDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Boulevard 75, 77-101b, 119992, Moscow, Russia.
Andrea AltieriEDASA Scientific, Scientific Park, Moscow State University, Leninskie Gory Boulevard 75, 77-101b, 119992, Moscow, Russia.
Asim K DebnathLaboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY, 10065, USA.ORCID 0000-0003-2761-0506
New York Blood Center · USLomonosov Moscow State University · RU

Funding

Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120R01AI104416 · NIAID · NEW YORK BLOOD CENTER · PI DEBNATH, ASIM K · 2013 to 2022
$7.9M
NIAID NIH HHS R01 AI104416
6 · The paper itself

Abstract

The pathway by which HIV-1 enters host cells is a prime target for novel drug discovery because of its critical role in the life cycle of HIV-1. The HIV-1 envelope glycoprotein gp120 plays an important role in initiating virus entry by targeting the primary cell receptor CD4. We explored the substitution of bulky molecular groups in region I in the NBD class of entry inhibitors. Previous attempts at bulky substituents in that region abolished antiviral activity, even though the binding site is hydrophobic. We synthesized a series of entry inhibitors containing the 1,3-benzodioxolyl moiety or its bioisostere, 2,1,3-benzothiadiazole. The introduction of the bulkier groups was well tolerated, and despite only minor improvements in antiviral activity, the selectivity index of these compounds improved significantly.

Indexed as

Anti-HIV AgentsBenzodioxolesBinding SitesHIV-1HIV Envelope Protein gp120HIV Reverse TranscriptaseHumansLeukocytes, MononuclearMolecular Docking SimulationMolecular StructureProtein BindingPyrrolesReverse Transcriptase InhibitorsStructure-Activity RelationshipThiadiazolesVirus InternalizationAnti-HIV AgentsBenzodioxolesHIV Envelope Protein gp120HIV Reverse TranscriptasePyrrolesreverse transcriptase, Human immunodeficiency virus 1Reverse Transcriptase InhibitorsThiadiazolesantiviral agentsENV-pseudovirusHIV-1reverse transcriptasestructure-activity relationships

Identifiers

PMID30257071
PMCPMC6446940
OpenAlexW2892875250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.